Stocks in play: Medicenna Therapeutics Corp.
Announced today that, as planned and previously announced, new data from two of its preclinical programs were presented orally at the Promise of Interleukin-2 Conference held in Paris over the weekend. Medicenna Therapeutics Corp. shares T.MDNA are trading up $0.03 at $2.25.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.